Additionally, as a personalized approach to safely discontinue anti-PD-1 monotherapy in patients with melanoma, 18fluorodeoxyglucose (18FDG)-PET/CT scanning has shown promise, yielding results that warrant validation [68]. The gene discussed is PDCD1; the disease is melanoma.